Genelux Statistics
Total Valuation
Genelux has a market cap or net worth of $125.23 million. The enterprise value is $101.52 million.
| Market Cap | 125.23M |
| Enterprise Value | 101.52M |
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genelux has 44.41 million shares outstanding. The number of shares has increased by 17.97% in one year.
| Current Share Class | 44.41M |
| Shares Outstanding | 44.41M |
| Shares Change (YoY) | +17.97% |
| Shares Change (QoQ) | +15.87% |
| Owned by Insiders (%) | 9.14% |
| Owned by Institutions (%) | 21.48% |
| Float | 36.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15,654.14 |
| Forward PS | n/a |
| PB Ratio | 5.46 |
| P/TBV Ratio | 5.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 12,689.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.68, with a Debt / Equity ratio of 0.11.
| Current Ratio | 3.68 |
| Quick Ratio | 3.60 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -127.28% and return on invested capital (ROIC) is -75.74%.
| Return on Equity (ROE) | -127.28% |
| Return on Assets (ROA) | -60.56% |
| Return on Invested Capital (ROIC) | -75.74% |
| Return on Capital Employed (ROCE) | -137.73% |
| Weighted Average Cost of Capital (WACC) | 7.25% |
| Revenue Per Employee | $308 |
| Profits Per Employee | -$1.29M |
| Employee Count | 26 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.44% in the last 52 weeks. The beta is 0.57, so Genelux's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -8.44% |
| 50-Day Moving Average | 2.95 |
| 200-Day Moving Average | 3.64 |
| Relative Strength Index (RSI) | 42.79 |
| Average Volume (20 Days) | 206,560 |
Short Selling Information
The latest short interest is 3.01 million, so 6.77% of the outstanding shares have been sold short.
| Short Interest | 3.01M |
| Short Previous Month | 3.18M |
| Short % of Shares Out | 6.77% |
| Short % of Float | 8.32% |
| Short Ratio (days to cover) | 15.57 |
Income Statement
In the last 12 months, Genelux had revenue of $8,000 and -$33.58 million in losses. Loss per share was -$0.85.
| Revenue | 8,000 |
| Gross Profit | 8,000 |
| Operating Income | -34.57M |
| Pretax Income | -33.58M |
| Net Income | -33.58M |
| EBITDA | -34.38M |
| EBIT | -34.57M |
| Loss Per Share | -$0.85 |
Balance Sheet
The company has $26.21 million in cash and $2.50 million in debt, with a net cash position of $23.71 million or $0.53 per share.
| Cash & Cash Equivalents | 26.21M |
| Total Debt | 2.50M |
| Net Cash | 23.71M |
| Net Cash Per Share | $0.53 |
| Equity (Book Value) | 22.92M |
| Book Value Per Share | 0.52 |
| Working Capital | 19.48M |
Cash Flow
In the last 12 months, operating cash flow was -$25.89 million and capital expenditures -$1.99 million, giving a free cash flow of -$27.88 million.
| Operating Cash Flow | -25.89M |
| Capital Expenditures | -1.99M |
| Depreciation & Amortization | 194,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -27.88M |
| FCF Per Share | -$0.63 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -432,112.50% |
| Pretax Margin | -419,762.50% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Genelux does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.97% |
| Shareholder Yield | -17.97% |
| Earnings Yield | -26.81% |
| FCF Yield | -22.26% |
Analyst Forecast
The average price target for Genelux is $17.50, which is 520.57% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.50 |
| Price Target Difference | 520.57% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 1,962.27% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genelux has an Altman Z-Score of -6.64 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.64 |
| Piotroski F-Score | 1 |